U-Blot® Research Grade Carlumab

Name: U-Blot® Research Grade Carlumab
SKU: WA2579
Availability: InStock

$9,999.00

Size:50ug

SKU: WA2579-50

Catalog No.: WA2579

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

Product details Specifications Q & A Education

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.: WA2579
SKU: WA2579-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: HC11
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Human
Isotype: IgG1-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: HC11, MCP-1, MCP1, Monocyte chemotactic protein 1, Monocyte chemotactic and activating factor, Small-inducible cytokine A2, SCYA2, MCAF, Monocyte secretory protein JE, C-C motif chemokine 2, Monocyte chemoattractant protein 1, CCL2
Species: --
Gene ID-1: P13500
Uniprot: --
Background: Carlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.<br>• MCP-1 gene (SCYA2) and schizophrenia: a case-control association study., PMID:15389752<br/>• The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study., PMID:19923858<br/>
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.